Keywords: Boehringer Ingelheim, Priaxon, R&D collaboration, Cancer

Boehringer Ingelheim and Priaxon collaborate on novel treatments for cancer

Article | 19 January 2010

German independent drug major Boehringer Ingelheim has entered into a worldwide collaboration with fellow Germany-based drug developer Priaxon to research and develop mdm2/p53 inhibitors for the treatment of cancer.

Under the terms of the deal, Boehringer Ingelheim will pay significant up-front and near-term payments to Priaxon including research funding to support further discovery efforts. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in